drugset
drugset / Trial / NCT05471674

Neoadjuvant Anti-PD1 in HCC

NCT05471674 ↗

Phase 2 Completed 20 enrolled Dr Tan-to CHEUNG
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2, single-arm trial designed to assess the clinical benefit of treatment with nivolumab administered in patients with untreated, borderline resectable HCC.

Timeline

Start
2020-07-03
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 3 mg/kg —

Indications

hepatocellular carcinoma